CompletedNCT05328297
A Study of JNJ-55308942 in the Treatment of Depression in bipolarity
Researchers compared JNJ-55308942 and placebo to find out how the approaches affected depression symptoms in people with bipolarity during a depressive episode.
Medication studyAges 18–64Multiple countries
Understand this study
What did researchers investigate?
Researchers compared JNJ-55308942 and placebo to find out how the approaches affected depression symptoms in people with bipolarity during a depressive episode.
Who was this study for?
This study was for people with bipolarity. Listed age limits: 18 years to 64 years. Other eligibility criteria applied.
- Listed locations
- Huntsville, United States · Little Rock, United States and 37 more locationsSee all locations and recruitment
- Activities
- Medication described in the protocol · Placebo comparator
- Compensation
- Payment and expense reimbursement have not been verified.
Study information
Study start dateStarted: June 3, 2022
- Recruitment status
- Completed
- Enrollment listed in the registry
- 116
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States, Canada, Poland, ...
- Age range
- From 18 Years to 64 Years
- Official registry ID
- NCT05328297
- Official title
Show the full official title
A Randomized, Stratified, Double-blind, Placebo-Controlled Study to Investigate the Efficacy, Safety and Tolerability of JNJ-55308942 in Bipolar Depression
Recruitment & locations
CompletedHuntsville, United States · Little Rock, United States · Lemon Grove, United States
36 more locations
- Torrance, United States
- Jacksonville, United States
- Orlando, United States
- Skokie, United States
- Indianapolis, United States
- Cherry Hill, United States
- Raleigh, United States
- Cleveland, United States
- Columbus, United States
- Media, United States
- Memphis, United States
- Austin, United States
- Fort Worth, United States
- Houston, United States
- Bellevue, United States
- West Vancouver, Canada
- Chatham, Canada
- Bialystok, Poland
- Bydgoszcz, Poland
- Gdansk, Poland
- Gorlice, Poland
- Katowice, Poland
- Lodz, Poland
- Poznan, Poland
- Siemianowice Śląskie, Poland
- Suchy Las, Poland
- Warsaw, Poland
- Wroclaw, Poland
- Barcelona, Spain
- Madrid, Spain
- Oviedo, Spain
- Pamplona, Spain
- Ponferrada, Spain
- Valencia, Spain
- Vigo, Spain
- Vitoria-Gasteiz, Spain
Questions about this study
What did researchers investigate?
Researchers compared JNJ-55308942 and placebo to find out how the approaches affected depression symptoms in people with bipolarity during a depressive episode.
Who is behind this study?
The study sponsor is Janssen Pharmaceutica N.V., Belgium.
Did this study involve medication?
Yes. The study involved medication, including JNJ-55308942 and Placebo.
Who was this study for?
This study was for people with bipolarity. Listed age limits: 18 years to 64 years. Other eligibility criteria applied.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meExplore related studies
Other studies that may be relevant based on condition, country, or study type.
CompletedEUCTR 2004-003826-92
"A Randomized, Parallel Group, Open Trial Examining the Safety, Efficacy and Tolerability of Fast Titration, 800mg/day by day 4, of Quetiapine Fumarate Compared to Standard Titration, 400mg/day by ...
Spain
CompletedNCT00223496
12- Week Open Label Treatment of Refractory Depression in bipolarity
United States
CompletedNCT02363738
12-Week Study Evaluating the Efficacy, Safety, and Tolerability of Adjunctive Infliximab for Bipolar I/II Depression
United States, Canada